News
TXMD
2.190
+0.46%
0.010
Weekly Report: what happened at TXMD last week (0907-0911)?
Weekly Report · 6d ago
Weekly Report: what happened at TXMD last week (0831-0904)?
Weekly Report · 09/07 09:58
TherapeuticsMD Inc. Stock Climbs 4.1%, Outperforms Market
Dow Jones · 09/02 20:35
Weekly Report: what happened at TXMD last week (0824-0828)?
Weekly Report · 08/31 10:03
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 08/26 12:06
TherapeuticsMD Inc. Stock Rallies 10.1%, Outperforms Market
Dow Jones · 08/25 20:32
Weekly Report: what happened at TXMD last week (0817-0821)?
Weekly Report · 08/24 10:04
Weekly Report: what happened at TXMD last week (0810-0814)?
Weekly Report · 08/17 10:05
TherapeuticsMD Q2 Results and Strategic Alternatives Review
TipRanks · 08/11 20:41
Therapeutics MD reports Q2 results
Seeking Alpha · 08/11 20:27
Press Release: TherapeuticsMD Announces Second Quarter 2026 Financial Results
Dow Jones · 08/11 20:00
Weekly Report: what happened at TXMD last week (0803-0807)?
Weekly Report · 08/10 10:01
Weekly Report: what happened at TXMD last week (0727-0731)?
Weekly Report · 08/03 10:00
Weekly Report: what happened at TXMD last week (0720-0724)?
Weekly Report · 07/27 10:04
Weekly Report: what happened at TXMD last week (0713-0717)?
Weekly Report · 07/20 10:01
Weekly Report: what happened at TXMD last week (0706-0710)?
Weekly Report · 07/13 10:02
TherapeuticsMD Inc. Stock Slides 6.6%, Underperforms Market
Dow Jones · 07/06 20:32
Weekly Report: what happened at TXMD last week (0629-0703)?
Weekly Report · 07/06 10:05
TherapeuticsMD Inc. Stock Advances 6.2%, Outperforms Market
Dow Jones · 06/29 20:34
Weekly Report: what happened at TXMD last week (0622-0626)?
Weekly Report · 06/29 10:01
More
Webull provides a variety of real-time TXMD stock news. You can receive the latest news about Therapeuticsmd Inc through multiple platforms. This information may help you make smarter investment decisions.
About TXMD
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).